{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:01:58Z","timestamp":1781100118150,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10637-025-01548-1","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:45:02Z","timestamp":1748357102000},"page":"679-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Orelabrutinib combined with rituximab and high-dose methotrexate as induction therapy in newly diagnosed primary central nervous system lymphoma"],"prefix":"10.1007","volume":"43","author":[{"given":"Xi-Bin","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Qin","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Qian","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"1548_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noac196","volume":"25","author":"K Hoang-Xuan","year":"2023","unstructured":"Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, Hottinger AF, Kasenda B, Lefranc F, Lossos A et al (2023) European association of neuro-oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol 25:37\u201353. https:\/\/doi.org\/10.1093\/neuonc\/noac196","journal-title":"Neuro Oncol"},{"key":"1548_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.radonc.2016.12.033","volume":"122","author":"MN Kerbauy","year":"2017","unstructured":"Kerbauy MN, Moraes FY, Lok BH, Ma J, Kerbauy LN, Spratt DE, Santos FP, Perini GF, Berlin A, Chung C et al (2017) Challenges and opportunities in primary CNS lymphoma: a systematic review. Radiother Oncol 122:352\u2013361. https:\/\/doi.org\/10.1016\/j.radonc.2016.12.033","journal-title":"Radiother Oncol"},{"key":"1548_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","volume":"9","author":"AJ Ferreri","year":"2023","unstructured":"Ferreri AJ, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L, Ponzoni M (2023) Primary central nervous system lymphoma. Nat Rev Dis Primers 9:29","journal-title":"Nat Rev Dis Primers"},{"key":"1548_CR4","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. The Lancet 374:1512\u20131520","journal-title":"The Lancet"},{"key":"1548_CR5","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, La Ros\u00e9e P, Schorb E (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. The Lancet Haematology 3:e217\u2013e227","journal-title":"The Lancet Haematology"},{"key":"1548_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/cancers16050860","volume":"16","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Ye J, Chen H, Zhou D, Ji C (2024) Efficacy and safety of BTKis in central nervous system lymphoma: a systematic review and meta-analysis. Cancers 16:860","journal-title":"Cancers"},{"key":"1548_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/neuonc\/noy193","volume":"21","author":"C Grommes","year":"2019","unstructured":"Grommes C, Nayak L, Tun HW, Batchelor TT (2019) Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol 21:306\u2013313. https:\/\/doi.org\/10.1093\/neuonc\/noy193","journal-title":"Neuro Oncol"},{"key":"1548_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P (2021) Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia 35:312\u2013332. https:\/\/doi.org\/10.1038\/s41375-020-01072-6","journal-title":"Leukemia"},{"key":"1548_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/neurolint14010009","volume":"14","author":"G Nepal","year":"2022","unstructured":"Nepal G, Khurana M, Bucheli DH, Bhandari S, Joshi U, Bhagat R, Rehrig JH, Pudasainee P, Shing YK, Ortiz JF (2022) Ibrutinib in refractory or relapsing primary central nervous system lymphoma: a systematic review. Neurol Int 14:99\u2013108","journal-title":"Neurol Int"},{"key":"1548_CR10","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1182\/blood-2024-201285","volume":"144","author":"Y Guo","year":"2024","unstructured":"Guo Y, Shan Y, Chang X, Zou D, Ma Q, Wei Y, Xu G, Wang Y, Tang J, Wang D (2024) Ibrutinib, rituximab, and high-dose methotrexate in newly diagnosed primary diffuse large B-cell lymphoma of the CNS: a prospective, phase II, single-arm, single-center study. Blood 144:6539","journal-title":"Blood"},{"key":"1548_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1158\/2643-3230.BCD-24-0156","volume":"6","author":"Y Gao","year":"2025","unstructured":"Gao Y, Ping L, Shan C, Huang H, Li Z, Zhou H, Lai M, Cai L, Bai B, Huang C (2025) High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase-II study. Blood Cancer Discov 6:191\u2013202","journal-title":"Blood Cancer Discov"},{"key":"1548_CR12","doi-asserted-by":"publisher","first-page":"114009","DOI":"10.1016\/j.ejmech.2021.114009","volume":"229","author":"F Ran","year":"2022","unstructured":"Ran F, Liu Y, Wang C, Xu Z, Zhang Y, Liu Y, Zhao G, Ling Y (2022) Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Eur J Med Chem 229:114009","journal-title":"Eur J Med Chem"},{"key":"1548_CR13","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1097\/HS9.0000000000000309","volume":"4","author":"M F\u00fcrstenau","year":"2020","unstructured":"F\u00fcrstenau M, Simon F, Cornely OA, Hicketier T, Eichhorst B, Hallek M, Mellinghoff SC (2020) Invasive aspergillosis in patients treated with ibrutinib. HemaSphere 4:e309","journal-title":"HemaSphere"},{"key":"1548_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/17460441.2023.2236547","volume":"18","author":"P Robak","year":"2023","unstructured":"Robak P, Witkowska M, Wolska-Washer A, Robak T (2023) The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies. Expert Opin Drug Discov 18:1065\u20131076","journal-title":"Expert Opin Drug Discov"},{"key":"1548_CR15","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/ajh.27064","volume":"98","author":"L Deng","year":"2023","unstructured":"Deng L, Li Z, Zhang H, Huang H, Hu J, Liu L, Liu T, Jin J, Zhu Z, Li W et al (2023) Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: a phase 2, multicenter, open-label study. Am J Hematol 98:1742\u20131750. https:\/\/doi.org\/10.1002\/ajh.27064","journal-title":"Am J Hematol"},{"key":"1548_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/01.HS9.0000843788.10370.07","volume":"6","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang W, Zhao D, Zhang W, Zhou D (2022) S224: preliminary results of a phase II study of orelabrutinib in combination with anti-PD-1 monoclonal antibody in refractory or relapsed primary CNS lymphoma. HemaSphere 6:125\u2013126","journal-title":"HemaSphere"},{"key":"1548_CR17","doi-asserted-by":"publisher","first-page":"e19041","DOI":"10.1200\/JCO.2024.42.16_suppl.e19041","volume":"42","author":"Y Xia","year":"2024","unstructured":"Xia Y, Cai Q, Zhang P, Tian X, Fang X (2024) Orelabrutinib, rituximab, temozolomide and high-dose methotrexate (RMOT) in newly diagnosed primary central nervous system lymphoma (PCNSL): a retrospective analysis on efficacy and safety. Am Soc Clin Oncol 42:e19041","journal-title":"Am Soc Clin Oncol"},{"key":"1548_CR18","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1182\/blood-2024-198355","volume":"144","author":"L Sheng","year":"2024","unstructured":"Sheng L, Ouyang G, Lai Y, Nie S, Wang D, Tang S, Pan Y, Xu K, Sun Y, Zhang P (2024) Preliminary data on the efficacy and safety of orelabrutinib combined with rituximab and methotrexate (ORM regimen) as first-line treatment for primary central nervous system lymphoma, and the exploration of cerebrospinal fluid Ctdna dynamic monitoring. Blood 144:4500","journal-title":"Blood"},{"key":"1548_CR19","doi-asserted-by":"publisher","first-page":"901797","DOI":"10.3389\/fonc.2022.901797","volume":"12","author":"C Yang","year":"2022","unstructured":"Yang C, Cui Y, Ren X, Li M, Yu K, Shen S, Jiang H, Li M, Zhang X, Zhao X et al (2022) Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series. Front Oncol 12:901797. https:\/\/doi.org\/10.3389\/fonc.2022.901797","journal-title":"Front Oncol"},{"key":"1548_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bjc.6605559","volume":"102","author":"M Joerger","year":"2010","unstructured":"Joerger M, Huitema A, Kr\u00e4henb\u00fchl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A (2010) Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic\u2013pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 102:673\u2013677","journal-title":"Br J Cancer"},{"key":"1548_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.16451","volume":"189","author":"E Schorb","year":"2020","unstructured":"Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, Ninkovic S, Eyre TA, Cummin T, Smith J (2020) Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system\u2013an international study of feasibility and efficacy in routine clinical practice. Br J Haematol 189:879\u2013887","journal-title":"Br J Haematol"},{"key":"1548_CR22","first-page":"436","volume":"133","author":"C Grommes","year":"2019","unstructured":"Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP (2019) Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma. Blood, J Am Soc Hematol 133:436\u2013445","journal-title":"Blood, J Am Soc Hematol"},{"key":"1548_CR23","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.1182\/blood-2024-202792","volume":"144","author":"X Xiao","year":"2024","unstructured":"Xiao X, Chen P, Jiang H, Li X, Xie J, Qian W (2024) Zanubrutinib in combination with R-MTX for newly diagnosed primary central nervous system lymphoma. Blood 144:6484","journal-title":"Blood"},{"key":"1548_CR24","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/annonc\/mdq712","volume":"22","author":"K Fritsch","year":"2011","unstructured":"Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V, Haug S, Ihorst G, Finke J, Illerhaus G (2011) Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 22:2080\u20132085","journal-title":"Ann Oncol"},{"key":"1548_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s10637-022-01219-5","volume":"40","author":"J-J Wu","year":"2022","unstructured":"Wu J-J, Wang W-H, Dong M, Ma S-S, Zhang X-D, Zhu L-N, Niu S-T, Ding M-J, Zhang J-M, Zhang L (2022) Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study. Invest New Drugs 40:650\u2013659","journal-title":"Invest New Drugs"},{"key":"1548_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","volume":"21","author":"H Yu","year":"2021","unstructured":"Yu H, Wang X, Li J, Ye Y, Wang D, Fang W, Mi L, Ding N, Wang X, Song Y (2021) Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Ther-oncolytics 21:158\u2013170","journal-title":"Mol Ther-oncolytics"},{"key":"1548_CR27","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajh.26826","volume":"98","author":"W Xu","year":"2023","unstructured":"Xu W, Zhou K, Wang T, Yang S, Liu L, Hu Y, Zhang W, Ding K, Zhou J, Gao S (2023) Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: multi-center, single-arm, open-label, phase 2 study. Am J Hematol 98:571\u2013579","journal-title":"Am J Hematol"},{"key":"1548_CR28","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1186\/s12885-023-11268-5","volume":"23","author":"K Zhong","year":"2023","unstructured":"Zhong K, Shi Y, Gao Y, Zhang H, Zhang M, Zhang Q, Cen X, Xue M, Qin Y, Zhao Y (2023) First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study. BMC Cancer 23:746","journal-title":"BMC Cancer"},{"key":"1548_CR29","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/jco.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O\u2019Brien S, Yenerel MN, Ill\u00e9s A, Kay N et al (2021) Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 39:3441\u20133452. https:\/\/doi.org\/10.1200\/jco.21.01210","journal-title":"J Clin Oncol"},{"key":"1548_CR30","doi-asserted-by":"publisher","first-page":"CNS51","DOI":"10.2217\/cns-2019-0022","volume":"9","author":"TJ Low","year":"2020","unstructured":"Low TJ, Peters BK (2020) Ibrutinib in primary central nervous system diffuse large B-cell lymphoma. CNS Oncology 9:CNS51","journal-title":"CNS Oncology"},{"key":"1548_CR31","doi-asserted-by":"publisher","first-page":"686768","DOI":"10.3389\/fimmu.2021.686768","volume":"12","author":"M Palma","year":"2021","unstructured":"Palma M, Mulder TA, \u00d6sterborg A (2021) BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects. Front Immunol 12:686768. https:\/\/doi.org\/10.3389\/fimmu.2021.686768","journal-title":"Front Immunol"},{"key":"1548_CR32","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/10428194.2024.2333985","volume":"65","author":"L Schaff","year":"2024","unstructured":"Schaff L, Nayak L, Grommes C (2024) Bruton\u2019s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances. Leuk Lymphoma 65:882\u2013894","journal-title":"Leuk Lymphoma"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01548-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:14:02Z","timestamp":1757175242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01548-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01548-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the ethics committee of the Second Affiliated Hospital of Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent for participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The subjects gave written informed consent for the publication of any associated data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}